Forensic/JJ
Body/NN
Fluid/NN
Identification/NN
by/IN
Analysis/NN
of/IN
Multiple/JJ
RNA/NN
Markers/NNS
Using/VBG
NanoString/JJ
Technology/NN
./.
====================
RNA/NN
analysis/NN
has/VBZ
become/VBN
a/DT
reliable/JJ
method/NN
of/IN
body/NN
fluid/NN
identification/NN
for/IN
forensic/JJ
use/NN
./.
====================
Previously/RB
,/,
we/PRP
developed/VBD
a/DT
combination/NN
of/IN
four/CD
multiplex/JJ
quantitative/JJ
PCR/NN
(/(
qRT-PCR/NN
)/)
probes/NNS
to/TO
discriminate/VB
four/CD
different/JJ
body/NN
fluids/NNS
(/(
blood/NN
,/,
semen/JJ
,/,
saliva/NN
,/,
and/CC
vaginal/JJ
secretion/NN
)/)
./.
====================
While/IN
those/DT
makers/VBZ
successfully/RB
identified/VBN
most/JJS
body/NN
fluid/NN
samples/NNS
,/,
there/EX
were/VBD
some/DT
cases/NNS
of/IN
false/JJ
positive/JJ
and/CC
negative/JJ
identification/NN
./.
====================
To/TO
improve/VB
the/DT
accuracy/NN
of/IN
the/DT
identification/NN
further/RBR
,/,
we/PRP
tried/VBD
to/TO
use/VB
multiple/JJ
markers/NNS
per/IN
body/NN
fluid/NN
and/CC
adopted/JJ
the/DT
NanoString/JJ
nCounter/NN
system/NN
instead/RB
of/IN
a/DT
multiplex/JJ
qRT-PCR/NN
system/NN
./.
====================
After/IN
measuring/VBG
tens/NNS
of/IN
RNA/NN
markers/NNS
,/,
we/PRP
evaluated/VBD
the/DT
accuracy/NN
of/IN
each/DT
marker/NN
for/IN
body/NN
fluid/NN
identification/NN
./.
====================
For/IN
body/NN
fluids/NNS
,/,
such/JJ
as/IN
blood/NN
and/CC
semen/JJ
,/,
each/DT
body/NN
fluid-specific/JJ
marker/NN
was/VBD
accurate/JJ
enough/IN
for/IN
perfect/JJ
identification/NN
./.
====================
However/RB
,/,
for/IN
saliva/NN
and/CC
vaginal/JJ
secretion/NN
,/,
no/DT
single/JJ
marker/NN
was/VBD
perfect/JJ
./.
====================
Thus/RB
,/,
we/PRP
designed/VBD
a/DT
logistic/JJ
regression/NN
model/NN
with/IN
multiple/JJ
markers/NNS
for/IN
saliva/NN
and/CC
vaginal/JJ
secretion/NN
and/CC
achieved/VBD
almost/RB
perfect/JJ
identification/NN
./.
====================
In/IN
conclusion/NN
,/,
the/DT
NanoString/JJ
nCounter/NN
is/VBZ
an/DT
efficient/JJ
platform/NN
for/IN
measuring/VBG
multiple/JJ
RNA/NN
markers/NNS
per/IN
body/NN
fluid/NN
and/CC
will/MD
be/VB
useful/JJ
for/IN
forensic/JJ
RNA/NN
analysis/NN
./.
====================
RNA/NN
analysis/NN
has/VBZ
emerged/VBN
as/IN
a/DT
reliable/JJ
method/NN
of/IN
body/NN
fluid/NN
identification/NN
for/IN
forensic/JJ
use/NN
[/(
1-7/CD
]/)
./.
====================
Conventionally/RB
,/,
immunological/JJ
,/,
enzymatic/JJ
,/,
and/CC
chemical/JJ
detection/NN
of/IN
specific/JJ
protein/NN
markers/NNS
is/VBZ
used/VBN
[/(
8-10/CD
]/)
./.
====================
For/IN
example/NN
,/,
prostate-specific/JJ
antigen/NN
has/VBZ
been/VBN
used/VBN
for/IN
semen/JJ
and/CC
hemoglobin/NN
for/IN
blood/NN
identification/NN
[/(
9/CD
,/,
10/CD
]/)
./.
====================
These/DT
assays/NNS
provide/VBP
important/JJ
information/NN
for/IN
crime/JJ
scenes/NNS
,/,
but/CC
they/PRP
can/MD
provide/VB
wrong/JJ
information/NN
because/IN
of/IN
cross-reactions/NNS
./.
====================
Recently/RB
,/,
several/JJ
body/NN
fluid-specific/JJ
mRNA/NN
markers/NNS
have/VBP
been/VBN
discovered/VBN
[/(
1-7/CD
]/)
:/:
Î²-spectrin/IN
(/(
SPTB/NN
)/)
,/,
porphobilinogen/NN
deaminase/NN
(/(
PBGD/NN
)/)
,/,
and/CC
hemoglobin/NN
alpha/NN
locus/NN
1/CD
(/(
HBA1/NN
)/)
for/IN
blood/NN
;/:
matrix/RB
metalloproteinase/NN
7/CD
and/CC
11/CD
(/(
MMP7/NN
and/CC
MMP11/NN
)/)
for/IN
menstrual/JJ
blood/NN
;/:
statherin/RB
(/(
STATH/NN
)/)
and/CC
histatin/NN
3/CD
(/(
HTN3/NN
)/)
for/IN
saliva/JJ
;/:
kallikrein/RB
3/CD
(/(
KLK3/NNP
)/)
and/CC
protamine/JJ
1/LS
and/CC
2/CD
(/(
PRM1/NN
and/CC
PRM2/NN
)/)
for/IN
semen/JJ
;/:
and/CC
human/JJ
beta-defensin/IN
1/LS
(/(
HBD-1/NN
)/)
and/CC
mucin/RB
4/CD
(/(
MUC4/NNP
)/)
for/IN
vaginal/JJ
secretion/NN
[/(
11/CD
]/)
./.
====================
After/IN
DNA/RNA/NN
co-extraction/NN
methods/NNS
were/VBD
applied/VBN
to/TO
the/DT
forensic/JJ
field/NN
,/,
RNA/NN
analysis/NN
has/VBZ
become/VBN
routine/NN
forensic/JJ
analysis/NN
[/(
12/CD
,/,
13/CD
]/)
./.
====================
RNA/NN
expression/NN
level/NN
is/VBZ
generally/RB
measured/VBN
using/VBG
reverse-transcription/JJ
and/CC
standard/JJ
end-point/JJ
PCR/NN
(/(
RT-PCR/NN
)/)
or/CC
quantitative/JJ
PCR/NN
(/(
qRT-PCR/NN
)/)
in/IN
a/DT
forensic/JJ
lab/NN
./.
====================
Recently/RB
,/,
using/VBG
microarray/NN
platforms/NNS
,/,
body/NN
fluid-specific/JJ
mRNA/NN
markers/NNS
were/VBD
identified/VBN
at/IN
a/DT
genome-wide/JJ
level/NN
[/(
14-16/CD
]/)
,/,
and/CC
multiplex/JJ
qRT-PCR/NN
probes/NNS
of/IN
these/DT
markers/NNS
were/VBD
developed/VBN
for/IN
one-step/JJ
identification/NN
of/IN
body/NN
fluid/NN
type/NN
[/(
7/CD
,/,
16/CD
]/)
./.
====================
Currently/RB
,/,
most/JJS
of/IN
the/DT
multiplex/JJ
qRT-PCR/NN
assays/NNS
use/VBP
a/DT
single/JJ
marker/NN
for/IN
each/DT
body/NN
fluid/NN
./.
====================
However/RB
,/,
using/VBG
a/DT
single/JJ
marker/NN
for/IN
each/DT
body/NN
fluid/NN
may/MD
lead/VB
to/TO
false/VB
positive/negative/JJ
identification/NN
,/,
as/IN
some/DT
markers/NNS
are/VBP
expressed/VBN
in/IN
more/RBR
than/IN
two/CD
types/NNS
of/IN
body/NN
fluid/NN
[/(
4-6/CD
]/)
./.
====================
Recently/RB
,/,
Roeder/NNP
and/CC
Haas/NNS
[/(
17/CD
]/)
suggested/VBD
a/DT
novel/JJ
approach/NN
of/IN
using/VBG
a/DT
minimum/JJ
of/IN
five/CD
mRNA/NN
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
and/CC
a/DT
scoring/JJ
method/NN
based/VBN
on/IN
multiple/JJ
markers/NNS
./.
====================
In/IN
this/DT
regard/NN
,/,
the/DT
multiplex/JJ
qRT-PCR/NN
system/NN
is/VBZ
not/RB
useful/JJ
,/,
because/IN
the/DT
number/NN
of/IN
fluorescent/JJ
dyes/NNS
in/IN
one/CD
reaction/NN
is/VBZ
limited/JJ
./.
====================
The/DT
NanoString/JJ
nCounter/RB
(/(
NanoString/JJ
Technologies/NNS
,/,
Seattle/JJ
,/,
WA/NN
,/,
USA/NNP
)/)
is/VBZ
a/DT
recent/JJ
platform/NN
that/DT
can/MD
quantify/VB
the/DT
expression/NN
of/IN
hundreds/VBZ
of/IN
mRNAs/NNS
in/IN
a/DT
single/JJ
reaction/NN
using/VBG
color-coded/JJ
molecular/JJ
barcodes/NNS
[/(
18/CD
,/,
19/CD
]/)
./.
====================
NanoString/VBG
nCounter/NN
is/VBZ
also/RB
known/VBN
as/IN
a/DT
sufficiently/RB
robust/JJ
method/NN
to/TO
measure/VB
expression/NN
in/IN
degraded/VBN
RNA/NN
samples/NNS
,/,
such/JJ
as/IN
formalin-fixed/VBN
paraffin-embedded/JJ
tissues/NNS
and/CC
crude/JJ
tissue/NN
lysates/NNS
[/(
18/CD
,/,
20/CD
]/)
./.
====================
Therefore/RB
,/,
applying/VBG
NanoString/JJ
nCounter/NN
to/TO
forensic/JJ
identification/NN
of/IN
body/NN
fluids/NNS
enables/VBZ
the/DT
digital/JJ
quantification/NN
of/IN
multiplexed/JJ
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
adopted/VBD
the/DT
NanoString/JJ
nCounter/NN
and/CC
designed/VBN
a/DT
panel/NN
of/IN
NanoString/JJ
probes/NNS
for/IN
multiple/JJ
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
We/PRP
tested/VBD
the/DT
multiple/JJ
markers/NNS
in/IN
a/DT
large/JJ
number/NN
of/IN
body/NN
fluid/NN
samples/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
found/VBD
that/IN
the/DT
new/JJ
multiplexed/JJ
method/NN
could/MD
improve/VB
the/DT
specificity/NN
and/CC
sensitivity/NN
of/IN
identification/NN
./.
====================
We/PRP
suggest/VBP
that/IN
using/VBG
multiple/JJ
mRNA/NN
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
could/MD
improve/VB
the/DT
accuracy/NN
of/IN
body/NN
fluid/NN
identification/NN
./.
====================
Sample/NN
collection/NN
and/CC
RNA/NN
preparation/NN
====================
Twelve/CD
samples/NNS
for/IN
each/DT
body/NN
fluid/NN
(/(
blood/NN
,/,
saliva/NN
,/,
semen/JJ
,/,
and/CC
vaginal/JJ
secretion/NN
)/)
were/VBD
collected/VBN
from/IN
healthy/JJ
Korean/JJ
volunteers/NNS
with/IN
informed/VBN
consent/NN
from/IN
the/DT
participants/NNS
./.
====================
The/DT
study/NN
protocol/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Boards/NNS
of/IN
Chungnam/JJ
National/JJ
University/NN
Hospital/JJ
./.
====================
To/TO
prepare/VB
total/JJ
RNA/NN
,/,
we/PRP
employed/VBD
the/DT
Qiagen/NN
RNeasy/NN
Mini/NN
kit/NN
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocol/NN
./.
====================
Extracted/JJ
total/JJ
RNA/NN
was/VBD
analyzed/VBN
using/VBG
Experion/NN
RNA/NN
StdSens/NNS
(/(
Bio-Rad/NNP
,/,
Hercules/NNS
,/,
CA/NNP
,/,
USA/NN
)/)
to/TO
check/VB
its/PRP$
quality/NN
and/CC
quantity/NN
./.
====================
NanoString/VBG
experiment/NN
====================
To/TO
validate/VB
the/DT
mRNA/NN
candidates/NNS
as/IN
body/NN
fluid/NN
specific/JJ
markers/NNS
,/,
NanoString/JJ
technology/NN
was/VBD
employed/VBN
./.
====================
Color-coded/JJ
barcodes/NNS
that/DT
represented/VBN
a/DT
single/JJ
target/NN
mRNA/NN
were/VBD
synthesized/VBN
,/,
targeting/VBG
18/CD
body/NN
fluid-specific/JJ
mRNA/NN
markers/NNS
,/,
and/CC
2/CD
endogenous/JJ
controls/NNS
for/IN
mRNA/NN
./.
====================
Briefly/RB
,/,
100/CD
ng/NN
of/IN
total/JJ
RNA/NN
was/VBD
hybridized/VBN
to/TO
the/DT
barcode/JJ
,/,
and/CC
then/RB
probe-mRNA/JJ
complexes/NNS
were/VBD
immobilized/VBN
on/IN
a/DT
streptavidin-coated/JJ
cartridge/NN
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocol/NN
./.
====================
Subsequently/RB
,/,
the/DT
cartridges/NNS
were/VBD
placed/VBN
in/IN
the/DT
digital/JJ
analyzer/NN
,/,
and/CC
barcodes/NNS
were/VBD
counted/VBN
./.
====================
All/DT
the/DT
counts/NNS
were/VBD
normalized/VBN
by/IN
the/DT
count/NN
of/IN
GAPDH/NN
barcodes/NNS
./.
====================
Statistical/JJ
analysis/NN
====================
We/PRP
applied/VBD
student/JJ
's/POS
t-test/JJS
to/TO
evaluate/VB
the/DT
significance/NN
of/IN
gene/NN
expression/NN
differences/NNS
between/IN
the/DT
tissue/NN
of/IN
interest/NN
and/CC
the/DT
other/JJ
three/CD
tissues/NNS
among/IN
the/DT
four/CD
body/NN
fluids/NNS
./.
====================
We/PRP
applied/VBD
receive/JJ
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
analysis/NN
to/TO
estimate/VB
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
each/DT
marker/NN
,/,
using/VBG
the/DT
ROCR/NN
package/NN
[/(
21/CD
]/)
of/IN
R/NN
software/RB
(/(
version/NN
2.6.1/CD
)/)
./.
====================
Again/RB
,/,
the/DT
four/CD
body/NN
fluids/NNS
were/VBD
divided/VBN
into/IN
two/CD
groups/NNS
:/:
a/DT
tissue/NN
of/IN
interest/NN
and/CC
the/DT
remaining/VBG
three/CD
tissues/NNS
among/IN
the/DT
four/CD
body/NN
fluids/NNS
./.
====================
Results/NNS
with/IN
a/DT
p-value/JJ
of/IN
</JJR
0.05/CD
were/VBD
considered/VBN
significant/JJ
./.
====================
Previously/RB
,/,
we/PRP
found/VBD
a/DT
dozen/JJ
mRNA/NN
markers/NNS
and/CC
developed/VBD
multiplex/JJ
qRT-PCR/NN
probes/NNS
for/IN
body/NN
fluid/NN
identification/NN
[/(
16/CD
]/)
./.
====================
But/CC
,/,
most/JJS
of/IN
the/DT
markers/NNS
,/,
except/IN
pro-platelet/NN
basic/JJ
protein/NN
(/(
PPBP/NN
)/)
,/,
were/VBD
not/RB
perfect/VB
in/IN
terms/NNS
of/IN
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
)/)
value/NN
(/(
AUC/NN
,/,
1/CD
)/)
./.
====================
To/TO
improve/VB
the/DT
accuracy/NN
of/IN
identification/NN
,/,
we/PRP
considered/VBD
a/DT
multiplexed/JJ
assay/NN
using/VBG
multiple/JJ
probes/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
While/IN
the/DT
multiplex/JJ
qRT-PCR/NN
system/NN
is/VBZ
limited/JJ
by/IN
the/DT
number/NN
of/IN
available/JJ
dyes/NNS
in/IN
a/DT
reaction/NN
,/,
the/DT
NanoString/JJ
nCounter/NN
can/MD
measure/VB
the/DT
expression/NN
of/IN
hundreds/VBZ
of/IN
RNAs/NNS
at/IN
once/RB
[/(
18/CD
]/)
./.
====================
So/RB
,/,
we/PRP
adopted/VBD
the/DT
NanoString/JJ
nCounter/NN
as/IN
the/DT
multiplexed/JJ
identification/NN
method/NN
using/VBG
multiple/JJ
RNA/NN
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
After/IN
designing/VBG
NanoString/JJ
probes/NNS
for/IN
18/CD
mRNA/NN
markers/NNS
(/(
four/CD
to/TO
five/CD
for/IN
each/DT
body/NN
fluid/NN
and/CC
two/CD
for/IN
controls/NNS
)/)
,/,
we/PRP
performed/VBD
NanoString/JJ
nCounter/NN
assays/NNS
with/IN
a/DT
total/JJ
of/IN
12/CD
RNA/NN
samples/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
got/VBP
a/DT
dozen/JJ
good/JJ
probes/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
according/VBG
to/TO
the/DT
following/VBG
criteria/NNS
:/:
1/CD
)/)
p/NN
</JJR
0.005/CD
and/CC
2/CD
)/)
body/NN
fluid-specific/JJ
expression/NN
pattern/NN
./.
====================
Results/NNS
of/IN
the/DT
other/JJ
probes/NNS
are/VBP
shown/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/CD
./.
====================
To/TO
test/VB
the/DT
value/NN
of/IN
each/DT
marker/NN
as/IN
a/DT
body/NN
fluid-specific/JJ
marker/NN
,/,
we/PRP
performed/VBD
ROC/NN
analysis/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
For/IN
blood-/NN
or/CC
semen-specific/JJ
markers/NNS
,/,
the/DT
identification/NN
accuracy/NN
was/VBD
perfect/JJ
(/(
AUC/NN
,/,
1/CD
)/)
./.
====================
But/CC
,/,
for/IN
saliva/NN
and/CC
vaginal/JJ
secretion/NN
,/,
no/DT
single/JJ
marker/NN
showed/VBD
perfect/JJ
accuracy/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
To/TO
improve/VB
the/DT
accuracy/NN
of/IN
saliva/NN
and/CC
vaginal/JJ
secretion/NN
identification/NN
,/,
we/PRP
tried/VBD
a/DT
combination/NN
of/IN
markers/NNS
using/VBG
logistic/JJ
regression/NN
analysis/NN
[/(
22/CD
]/)
./.
====================
We/PRP
evaluated/VBD
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
each/DT
marker/NN
and/CC
then/RB
evaluated/VBD
the/DT
performance/NN
of/IN
the/DT
combined/JJ
markers/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
For/IN
saliva/NN
and/CC
vaginal/JJ
identification/NN
,/,
using/VBG
two/CD
markers/NNS
significantly/RB
improved/VBN
the/DT
identification/NN
accuracy/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
Therefore/RB
,/,
we/PRP
could/MD
identify/VB
each/DT
body/NN
fluid/NN
with/IN
multiple/JJ
makers/VBZ
for/IN
each/DT
body/NN
fluid/NN
using/VBG
the/DT
NanoString/JJ
nCounter/NN
quite/RB
accurately/RB
./.
====================
Previously/RB
,/,
we/PRP
developed/VBD
multiplex/JJ
qRT-PCR/NN
probes/NNS
that/DT
used/VBN
one/CD
specific/JJ
mRNA/NN
marker/NN
for/IN
each/DT
body/NN
fluid/NN
[/(
16/CD
]/)
./.
====================
In/IN
that/DT
work/NN
,/,
blood/NN
was/VBD
perfectly/RB
identified/VBN
using/VBG
a/DT
single/JJ
marker/NN
,/,
PPBP/NN
./.
====================
However/RB
,/,
for/IN
other/JJ
body/NN
fluids/NNS
,/,
such/JJ
as/IN
vaginal/JJ
secretion/NN
and/CC
saliva/NN
,/,
it/PRP
was/VBD
difficult/JJ
to/TO
find/VB
out/IN
markers/NNS
that/WDT
perfectly/RB
discriminated/JJ
them/PRP
from/IN
other/JJ
body/NN
fluids/NNS
./.
====================
For/IN
example/NN
,/,
as/IN
saliva/JJ
and/CC
vaginal/JJ
secretion/NN
showed/VBD
similar/JJ
expression/NN
patterns/NNS
,/,
many/JJ
selected/VBN
body/NN
fluid-specific/JJ
markers/NNS
were/VBD
expressed/VBN
in/IN
both/DT
body/NN
fluids/NNS
./.
====================
This/DT
problem/NN
led/VBD
us/PRP
to/TO
consider/VB
a/DT
combination/NN
of/IN
multiple/JJ
markers/NNS
for/IN
perfect/JJ
identification/NN
./.
====================
A/DT
limit/VB
in/IN
the/DT
number/NN
of/IN
markers/NNS
that/WDT
can/MD
be/VB
assessed/VBN
in/IN
a/DT
reaction/NN
was/VBD
the/DT
biggest/JJS
problem/NN
when/WRB
we/PRP
considered/VBD
the/DT
use/NN
of/IN
multiple/JJ
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
./.
====================
As/IN
the/DT
number/NN
of/IN
different/JJ
fluorescent/JJ
dyes/NNS
available/JJ
in/IN
a/DT
qRT-PCR/NN
reaction/NN
is/VBZ
limited/JJ
(/(
i.e./FW
,/,
five/CD
)/)
,/,
we/PRP
considered/VBD
a/DT
new/JJ
method/NN
that/DT
can/MD
measure/VB
at/IN
least/JJS
10/CD
RNAs/NNS
at/IN
once/RB
./.
====================
Fortunately/RB
,/,
the/DT
recently/RB
developed/VBD
NanoString/JJ
nCounter/NN
allowed/VBD
us/PRP
to/TO
measure/VB
hundreds/VBZ
of/IN
probes/NNS
in/IN
a/DT
single/JJ
reaction/NN
;/:
so/RB
,/,
we/PRP
adopted/VBD
the/DT
NanoString/JJ
platform/NN
in/IN
our/PRP$
body/NN
fluid/NN
identification/NN
project/VB
./.
====================
Measuring/VBG
the/DT
expression/NN
of/IN
multiple/JJ
makers/VBZ
per/FW
body/NN
fluid/NN
has/VBZ
a/DT
big/NN
advantage/NN
./.
====================
As/IN
we/PRP
have/VBP
shown/VBN
,/,
by/IN
using/VBG
two/CD
markers/NNS
for/IN
each/DT
body/NN
fluid/NN
,/,
we/PRP
could/MD
identify/VB
saliva/NN
and/CC
vaginal/JJ
secretions/NNS
that/WDT
were/VBD
not/RB
identified/VBN
perfectly/RB
by/IN
a/DT
single/JJ
marker/NN
./.
====================
As/IN
we/PRP
could/MD
identify/VB
blood/NN
and/CC
semen/JJ
perfectly/RB
using/VBG
only/RB
one/CD
marker/NN
per/IN
body/NN
fluid/NN
,/,
we/PRP
conclude/VBP
that/IN
a/DT
total/JJ
of/IN
10/CD
markers/NNS
is/VBZ
enough/IN
to/TO
identify/VB
four/CD
different/JJ
body/NN
fluids/NNS
in/IN
one/CD
reaction/NN
./.
====================
In/IN
this/DT
regard/NN
,/,
the/DT
NanoString/JJ
nCounter/NN
is/VBZ
a/DT
promising/JJ
platform/NN
that/DT
allows/VBZ
us/PRP
to/TO
identify/VB
each/DT
body/NN
fluid/NN
in/IN
one/CD
reaction/NN
with/IN
high/JJ
accuracy/NN
./.
====================
Expression/NN
patterns/NNS
of/IN
selected/VBN
mRNA/NN
markers/NNS
in/IN
our/PRP$
NanoString/NN
nCounter/NN
assay/NN
dataset/NN
./.
====================
Each/DT
count/NN
was/VBD
normalized/VBN
to/TO
GAPDH/NN
mRNA/NN
./.
====================
(/(
A/NN
)/)
Blood/NN
./.
====================
(/(
B/NN
)/)
Saliva/NN
./.
====================
(/(
C/NN
)/)
Semen/NN
./.
====================
(/(
D/NN
)/)
Vaginal/JJ
./.
====================
Receive/JJ
operating/VBG
characteristic/JJ
analysis/NN
of/IN
selected/VBN
mRNA/NN
markers/NNS
in/IN
our/PRP$
NanoString/NN
nCounter/NN
assay/NN
dataset/NN
./.
====================
AUC/NN
,/,
area/NN
under/IN
the/DT
curve/NN
./.
====================
(/(
A/NN
)/)
Blood/NN
./.
====================
(/(
B/NN
)/)
Saliva/NN
./.
====================
(/(
C/NN
)/)
Semen/NN
./.
====================
(/(
D/NN
)/)
Vaginal/JJ
./.
====================
Workflow/IN
for/IN
the/DT
selection/NN
of/IN
multiple/JJ
mRNA/NN
markers/NNS
./.
====================
AUC/NN
,/,
area/NN
under/IN
the/DT
curve/NN
./.
====================
Performance/NN
of/IN
body/NN
fluid/NN
identification/NN
using/VBG
multiple/JJ
markers/NNS
====================
